Bon Natural Life Ltd (NASDAQ: BON)

Bon Natural Life Limited is a holding company incorporated under the laws of the Cayman Islands that oversees a group of operating subsidiaries primarily located in the People’s Republic of China. The company’s core business involves the manufacture and sale of natural ingredients used in personal care, health supplements, and functional food products. Its product portfolio includes fragrance compounds such as ambroxide and sclareol derived from clary sage, bioactive food ingredients like apple polyphenol, stachyose, milk thistle extract and pomegranate extract, and powder‑based nutritional supplements. All manufacturing activities are carried out through its wholly owned subsidiary Xi’an App‑Chem Bio(Tech) Co., Ltd. and its various sub‑sidiaries.

Bon Natural Life Limited generates revenue by selling its natural ingredients to third‑party manufacturers in the personal care, cosmetic, food and beverage, and pharmaceutical sectors. The company’s fragrance chemicals are sold to perfume and detergent producers, while its health‑supporting ingredients such as stachyose and apple polyphenol are supplied to makers of powder drinks, dietary supplements and functional foods. In addition, the firm offers custom formulation development and technical support services that add value to its product sales. Sales are conducted mainly through direct distributors within China and, to a lesser extent, to overseas customers in Europe.

Bon Natural Life Limited competes with established players in the natural ingredients and health supplement markets, including Chenguang Biotech Group Co., Ltd., Tong Ren Tang Group, BY‑HEALTH, and multinational firms such as Koninklijke DSM N. V., Symrise AG and Givaudan SA. Despite facing larger rivals with greater scale and brand recognition, the company highlights its competitive edge in advanced bio‑manufacturing processes, such as a six‑step bio‑synthesis route for ambroxide that it claims yields higher purity and output than traditional chemical synthesis. It also points to a first‑mover advantage in products targeting the human microbiome, a growing niche where it has secured recognition as a key enterprise during the COVID‑19 pandemic for its stachyose offerings. The firm’s patent portfolio, which includes seventeen granted patents in China, further supports its technological differentiation.

Bon Natural Life Limited serves a diverse customer base that includes fragrance and perfume manufacturers, health supplement producers, food and beverage companies, and personal care and cosmetic firms. Specific customers disclosed in the filing are Tianjin Mingrunbaili Trade Co., Ltd., Shanghai Yunsheng International Trade Co., Ltd., OQEMA Ltd and Symrise Private Limited. The company notes that a small number of large customers account for a significant portion of its revenue, with two customers representing 24.3% and 15.7% of total sales in the fiscal year ended September 30, 2025.